{"name":"Seqirus","slug":"seqirus","ticker":"","exchange":"","domain":"","description":"CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":23,"colorKey":"oncology","drugs":[{"name":"Seqirus QIV","genericName":"Seqirus QIV","slug":"seqirus-qiv","indication":"Prevention of influenza disease caused by four different strains of the influenza virus","status":"phase_3"},{"name":"aQIV","genericName":"aQIV","slug":"aqiv","indication":"Other","status":"phase_3"},{"name":"licensed QIVr","genericName":"licensed QIVr","slug":"licensed-qivr","indication":"Prevention of influenza disease caused by four different strains of the influenza virus","status":"phase_3"},{"name":"licensed aQIV","genericName":"licensed aQIV","slug":"licensed-aqiv","indication":"Seasonal influenza prevention in adults","status":"phase_3"},{"name":"Adjuvanted QIV (aQIV)","genericName":"Adjuvanted QIV (aQIV)","slug":"adjuvanted-qiv-aqiv","indication":"Seasonal influenza prevention in adults","status":"phase_3"},{"name":"Adjuvanted, trivalent subunit influenza vaccine","genericName":"Adjuvanted, trivalent subunit influenza vaccine","slug":"adjuvanted-trivalent-subunit-influenza-vaccine","indication":"Other","status":"phase_1"},{"name":"Afluria Influenza Vaccine","genericName":"Afluria Influenza Vaccine","slug":"afluria-influenza-vaccine","indication":"Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older.","status":"phase_2"},{"name":"CSL Influenza Vaccine","genericName":"CSL Influenza Vaccine","slug":"csl-influenza-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"marketed"},{"name":"CSL Limited Influenza Vaccine","genericName":"CSL Limited Influenza Vaccine","slug":"csl-limited-influenza-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"marketed"},{"name":"CSL Limited Influenza Virus Vaccine","genericName":"CSL Limited Influenza Virus Vaccine","slug":"csl-limited-influenza-virus-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"marketed"},{"name":"CSL412","genericName":"CSL412","slug":"csl412","indication":"Influenza prevention","status":"phase_2"},{"name":"Comparator QIV","genericName":"Comparator QIV","slug":"comparator-qiv","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"Enzira® vaccine","genericName":"Enzira® vaccine","slug":"enzira-vaccine","indication":"Seasonal influenza prevention in adults","status":"marketed"},{"name":"Flucelvax Quadrivalent Influenza Vaccine","genericName":"Flucelvax Quadrivalent Influenza Vaccine","slug":"flucelvax-quadrivalent-influenza-vaccine","indication":"Other","status":"phase_2"},{"name":"Flucelvax Trivalent Influenza Vaccine","genericName":"Flucelvax Trivalent Influenza Vaccine","slug":"flucelvax-trivalent-influenza-vaccine","indication":"Other","status":"phase_2"},{"name":"Investigational aQIVc","genericName":"Investigational aQIVc","slug":"investigational-aqivc","indication":"Seasonal influenza prevention in adults","status":"phase_3"},{"name":"Non-adjuvanted QIV","genericName":"Non-adjuvanted QIV","slug":"non-adjuvanted-qiv","indication":"Seasonal influenza prevention in adults","status":"phase_3"},{"name":"Non-influenza Comparator Vaccine","genericName":"Non-influenza Comparator Vaccine","slug":"non-influenza-comparator-vaccine","indication":"Phase 3 comparator vaccine (specific indication unknown without trial protocol details)","status":"phase_3"},{"name":"Novartis Seasonal Influenza Vaccine","genericName":"Novartis Seasonal Influenza Vaccine","slug":"novartis-seasonal-influenza-vaccine","indication":"Prevention of seasonal influenza in individuals aged 6 months and older","status":"phase_3"},{"name":"QIV or TIV","genericName":"QIV or TIV","slug":"qiv-or-tiv","indication":"Prevention of influenza disease caused by influenza A subtype viruses and type B viruses","status":"phase_3"},{"name":"QIVc","genericName":"QIVc","slug":"qivc","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"Seqirus Quadrivalent Inactivated Influenza Vaccine","genericName":"Seqirus Quadrivalent Inactivated Influenza Vaccine","slug":"seqirus-quadrivalent-inactivated-influenza-vaccine","indication":"Prevention of influenza disease caused by four different strains of the influenza virus","status":"phase_3"},{"name":"aH5N1c","genericName":"aH5N1c","slug":"ah5n1c","indication":"Prevention of influenza caused by the H5N1 subtype of the influenza A virus","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CSL425","genericName":"CSL425","slug":"csl425","indication":"Prevention of respiratory syncytial virus (RSV) disease in infants and young children","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Novartis Investigational H5N1 vaccine","genericName":"Novartis Investigational H5N1 vaccine","slug":"novartis-investigational-h5n1-vaccine","indication":"Prevention of H5N1 avian influenza infection in at-risk populations","status":"phase_3"}]}],"pipeline":[{"name":"Seqirus QIV","genericName":"Seqirus QIV","slug":"seqirus-qiv","phase":"phase_3","mechanism":"Seqirus QIV is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses.","indications":["Prevention of influenza disease caused by four different strains of the influenza virus"],"catalyst":""},{"name":"aQIV","genericName":"aQIV","slug":"aqiv","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"licensed QIVr","genericName":"licensed QIVr","slug":"licensed-qivr","phase":"phase_3","mechanism":"QIVr is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses.","indications":["Prevention of influenza disease caused by four different strains of the influenza virus"],"catalyst":""},{"name":"licensed aQIV","genericName":"licensed aQIV","slug":"licensed-aqiv","phase":"phase_3","mechanism":"aQIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four circulating influenza virus strains.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"Adjuvanted QIV (aQIV)","genericName":"Adjuvanted QIV (aQIV)","slug":"adjuvanted-qiv-aqiv","phase":"phase_3","mechanism":"Adjuvanted QIV (aQIV) is a quadrivalent influenza vaccine enhanced with an adjuvant to boost immune response against four influenza virus strains.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"Adjuvanted, trivalent subunit influenza vaccine","genericName":"Adjuvanted, trivalent subunit influenza vaccine","slug":"adjuvanted-trivalent-subunit-influenza-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Afluria Influenza Vaccine","genericName":"Afluria Influenza Vaccine","slug":"afluria-influenza-vaccine","phase":"phase_2","mechanism":"Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus.","indications":["Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older."],"catalyst":""},{"name":"CSL Influenza Vaccine","genericName":"CSL Influenza Vaccine","slug":"csl-influenza-vaccine","phase":"marketed","mechanism":"This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"CSL Limited Influenza Vaccine","genericName":"CSL Limited Influenza Vaccine","slug":"csl-limited-influenza-vaccine","phase":"marketed","mechanism":"This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"CSL Limited Influenza Virus Vaccine","genericName":"CSL Limited Influenza Virus Vaccine","slug":"csl-limited-influenza-virus-vaccine","phase":"marketed","mechanism":"This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"CSL412","genericName":"CSL412","slug":"csl412","phase":"phase_2","mechanism":"CSL412 is a vaccine.","indications":["Influenza prevention"],"catalyst":""},{"name":"CSL425","genericName":"CSL425","slug":"csl425","phase":"phase_2","mechanism":"CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection.","indications":["Prevention of respiratory syncytial virus (RSV) disease in infants and young children"],"catalyst":""},{"name":"Comparator QIV","genericName":"Comparator QIV","slug":"comparator-qiv","phase":"phase_3","mechanism":"Comparator QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"Enzira® vaccine","genericName":"Enzira® vaccine","slug":"enzira-vaccine","phase":"marketed","mechanism":"Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"Flucelvax Quadrivalent Influenza Vaccine","genericName":"Flucelvax Quadrivalent Influenza Vaccine","slug":"flucelvax-quadrivalent-influenza-vaccine","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Flucelvax Trivalent Influenza Vaccine","genericName":"Flucelvax Trivalent Influenza Vaccine","slug":"flucelvax-trivalent-influenza-vaccine","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Investigational aQIVc","genericName":"Investigational aQIVc","slug":"investigational-aqivc","phase":"phase_3","mechanism":"aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"Non-adjuvanted QIV","genericName":"Non-adjuvanted QIV","slug":"non-adjuvanted-qiv","phase":"phase_3","mechanism":"Non-adjuvanted QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four influenza virus strains without added adjuvant components.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"Non-influenza Comparator Vaccine","genericName":"Non-influenza Comparator Vaccine","slug":"non-influenza-comparator-vaccine","phase":"phase_3","mechanism":"A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen.","indications":["Phase 3 comparator vaccine (specific indication unknown without trial protocol details)"],"catalyst":""},{"name":"Novartis Investigational H5N1 vaccine","genericName":"Novartis Investigational H5N1 vaccine","slug":"novartis-investigational-h5n1-vaccine","phase":"phase_3","mechanism":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus.","indications":["Prevention of H5N1 avian influenza infection in at-risk populations"],"catalyst":""},{"name":"Novartis Seasonal Influenza Vaccine","genericName":"Novartis Seasonal Influenza Vaccine","slug":"novartis-seasonal-influenza-vaccine","phase":"phase_3","mechanism":"The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection.","indications":["Prevention of seasonal influenza in individuals aged 6 months and older"],"catalyst":""},{"name":"QIV or TIV","genericName":"QIV or TIV","slug":"qiv-or-tiv","phase":"phase_3","mechanism":"QIV or TIV is a vaccine that stimulates the body's immune system to produce antibodies against influenza.","indications":["Prevention of influenza disease caused by influenza A subtype viruses and type B viruses","Prevention of influenza disease in individuals 6 months of age and older"],"catalyst":""},{"name":"QIVc","genericName":"QIVc","slug":"qivc","phase":"phase_3","mechanism":"QIVc is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"Seqirus Quadrivalent Inactivated Influenza Vaccine","genericName":"Seqirus Quadrivalent Inactivated Influenza Vaccine","slug":"seqirus-quadrivalent-inactivated-influenza-vaccine","phase":"phase_3","mechanism":"This vaccine induces an immune response against multiple influenza strains.","indications":["Prevention of influenza disease caused by four different strains of the influenza virus"],"catalyst":""},{"name":"aH5N1c","genericName":"aH5N1c","slug":"ah5n1c","phase":"phase_3","mechanism":"aH5N1c is a vaccine that stimulates the body's immune response to the H5N1 subtype of the influenza A virus.","indications":["Prevention of influenza caused by the H5N1 subtype of the influenza A virus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPd1ZXZTFyT2x6aWdtbzRaRFRaT1NkMVBXZ09KcXdieHhjX0dxTGNjRVpLSERLb09SNjRhYkxHa3lmZjV1Y05DcnF5YXN0a1lURGRwSGlXTC1OYVFhblN4bnNpczh3R093QzZEVVZYNkpsMF9RZzExV1lKUzFwaXM4TUVsLVZGVFdjOEdGU2FfT2k2dS0tY0s5UVpQc0JOZXk2?oc=5","date":"2026-02-12","type":"earnings","source":"Fierce Pharma","summary":"CSL's bleak earnings report helps explain why it made CEO switch - Fierce Pharma","headline":"CSL's bleak earnings report helps explain why it made CEO switch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQLVlYMGl0OVV2WXhfVW9oX29tNVIzMGd2OFRlekdiLVZMa3VGUnZIellEeGZfVFpMSkROTFpndG8xNWVyakRPdGJmakdpd0hpRjFUYUtLQTVGSlloQTg2Q055MWcxUjdlSHE3RTkza2pvVWM4VUl4TTZEc2hHYnVBVE5Zb1BUOUotb0N0ZGVXMVdMeW5zSDZQdjFGdzVEb3Zpa3BUZXVQWXhBMkZzaWVfdmtvSEVIS3hwX2IycDJVb1g?oc=5","date":"2026-02-10","type":"pipeline","source":"Fierce Pharma","summary":"Under pressure, CSL chief hits exit as former Seqirus exec steps into interim role - Fierce Pharma","headline":"Under pressure, CSL chief hits exit as former Seqirus exec steps into interim role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQWV5YVUtRF9JN3J3Z0lLdEl2dWhyd0NCR0k2X2U4S3RqZG9XZlY5OWhrdVhqbElkMkszZ0xfbEtKOTE1dEVsNEtDcTRLNGgxNnhJWlUyTWtXNy05RFVuUXhnS2doUVg0eE1hdkRyX1JuaVF6WWpPOGIxelJkcFM5eUkwYnVKNXRXZ2h5WGJrYXZ2T2JHRzhZbXlPTEpiX1VMWlJRRnBhYW5VU05KbmlQTWJacFJLOGJiVGhVQXc5SQ?oc=5","date":"2025-12-09","type":"pipeline","source":"Fierce Pharma","summary":"Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia - Fierce Pharma","headline":"Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPaTFJcFBxRFhtdnExSFVyNUpiYUlTOXNqX19KVmctaWZYOWU3M3dQaWg1eHkxdkMwaFZfWmhtbFRJU195a2hGODdNR1JWbzhqMzRRcHI1d25zWlB0Tks3THVRUGRoTFJyOHZJQnpZT3dJSUFhM0YwWlZ4cl9ERTZrYnBWUndHYW5rcDNjZmozM3hvd0dldGltZUV1dW9iZmEzeWJR?oc=5","date":"2025-10-30","type":"pipeline","source":"Fierce Pharma","summary":"CSL Seqirus strikes flu shot supply, production pact with Saudi Arabia - Fierce Pharma","headline":"CSL Seqirus strikes flu shot supply, production pact with Saudi Arabia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNRzJ1WXhyeDBIMUFZQktYazJJNnRlQTgzX3JwQk5pU096M2hTNlZ0RWZwSjFESGVnNEgxa3g3dmppaUczYjRGVkNxX2VpYWVTQkxNOGNVdjQwUTM1UFl3VWdjVmZqRm91YUd5bU1YOGZ1MFJsZ2FFM2dhZ1RPNF9HS3lZZEZCM28zeWVFVzdn?oc=5","date":"2025-10-29","type":"pipeline","source":"pharmaphorum","summary":"Falling flu vaccine sales in US stall CSL's Seqirus spinout - pharmaphorum","headline":"Falling flu vaccine sales in US stall CSL's Seqirus spinout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOWkJEcmNGZUJ1MWJBMnF4Um5UUV81U2FIR1dYcGRuV2ZNaTVrV0JiVWtvaFlpT29EOFBDVkc3akU5bFNCa1FMQURRZGN3VFpkZFQxUlhjSmpkcU5lTHZDdU00RWJjU2ZRRHVOVEloMExqVG9pQWtaaERhQldzNHE2SXFMbVlSdzZ5aFN5bTJuWDd1aGp6Sk1qVnhYRkw2RzBSUmNZ?oc=5","date":"2025-10-28","type":"pipeline","source":"Fierce Pharma","summary":"CSL delays flu vaccine unit spinoff as US immunization rates plummet - Fierce Pharma","headline":"CSL delays flu vaccine unit spinoff as US immunization rates plummet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4yUFFiQ2wwUzYtbk52c2Z2R0lCb3RJUmpVVDM1U1VPRVRQc0dqZjVHRDlSNjdjNnJnOWlGVXNNWmNKZzQ3ZktFZ3BWWldKdXJQMkRz?oc=5","date":"2025-08-05","type":"pipeline","source":"FirstWord Pharma","summary":"HHS pulls funding from 22 mRNA vaccine projects - FirstWord Pharma","headline":"HHS pulls funding from 22 mRNA vaccine projects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQSXJmaVRmdlQ4S3hWdkhScXB6SzgzVV8zMWwzbks5dlJGY0RsdGw4bl9Ndjc3LVN1MU9ZcFFoWG10UVlYcHQxUV9TLTBCcFVPOVNnTm1pX0FYdDJWcXpmb0h4T0hvMVZhUHhwQmhiNTR6RWU4VUdiYmFEdjQwakI0WGxBd3dGTkJxQnJ5NDJScTh3V3JEWUFRSll4NHkxVDRadW5yZQ?oc=5","date":"2025-07-11","type":"pipeline","source":"The Pharma Letter","summary":"CSL Seqirus ships first flu jabs for the US 2025/26 season - The Pharma Letter","headline":"CSL Seqirus ships first flu jabs for the US 2025/26 season","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5pYVVlTGpDTUt2Z092V04zVnBsdXlydEw0YU1nak9IV2c2Rnk5VFl5aFhMVmVXc1hybm9icURwVnMwbkdNUlFHRVduaDZvYnNkTlZQdzZPUkpucXRRMG5SRlRNVWwzdGxwOUQ3cFhR0gFyQVVfeXFMTTZfOUF4M3ZaUU83MHBvUjBRS1FKdmtITXJycV9CYjAtU3hScHNVOUxfclkxX2ZqS0M5QXJrZEZEbW5vbGlqMXN6Y2k0NTdleU9OLTFHSFlyMUxUcllycFNxUGQ3bnIyN0p1ek9CNm41R0V3?oc=5","date":"2025-06-18","type":"pipeline","source":"koreabiomed.com","summary":"CSL Seqirus taps Samjin Pharm to expand flu shot access in Korea - koreabiomed.com","headline":"CSL Seqirus taps Samjin Pharm to expand flu shot access in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPcFJOSmUyU0RQV0twUk04bWloTjZQWk9KR3NtZ192V2N5dFhXS0NyUXJwVHZ3LWxOSjJfUURNYTVPM1FTeG1tSS1PSm91S2s4bk9OeV9DVDdVYmtNNF9KenE5ZWdUc2w5ZkxLWWhIZkxPcmNoczk3dVlhLUhZdWpabzJRYWV0bkNVdmtRcTFybU4ya25vSGR0c0J0UzJDaWw2SGhxbXFJMUV4UUZZLUlZX3I4LWxMM2dCNlF3aFZmSDVnRnk3LUE?oc=5","date":"2024-09-26","type":"pipeline","source":"Fierce Pharma","summary":"CSL Seqirus picks up $121M BARDA contract for bird flu pandemic preparedness - Fierce Pharma","headline":"CSL Seqirus picks up $121M BARDA contract for bird flu pandemic preparedness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMzdPS0NGYTJsT0FkOFYwSDl1UUh3XzJvd2dZNGo0Q2hSQ3VGUVRrNTF2Z0xHa3VnZ2E2a2RRQ1pZS1JDa2ZrZWJFdnR1c3ljbjRMMnVuT0ZpMGZJZkNUeUc5RHF1TXlQalRPdnJsSjVaVDZzaXczM3B3UWRiS2hIWmRsTVVMdUE5Z1FtcmJ3NU9XVGI3X01oX09KZmxNSzhLYzdtVTlFeUo1R1o4Rk1nUDUzLU9yRkZmc0lV?oc=5","date":"2024-07-11","type":"pipeline","source":"Fierce Pharma","summary":"Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season - Fierce Pharma","headline":"Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV3RlM3RGWjdjTkVNd2lBN1piUjFtOXJhS3M0aVJnR0EwamM0dFJLcmtSQUhyTFQ4V1lrUWUzYVVsa1FiN3N5d2xGTWtxRkg4Y29IWHVSX3p4Mk9EeXZrLUEyZ2kzaUJNUlZzWE4tZ3N5TVlXWXRUNVZJMjdrYkpmX19va0I0Njk2TF8xN2JYaGlmdFJnVWszU1IwZWFLVzkwbkhhVXdKOU4?oc=5","date":"2022-06-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"Seqirus Vaccine Manufacturing Facility Expansion, Holly Springs, NC - Pharmaceutical Technology","headline":"Seqirus Vaccine Manufacturing Facility Expansion, Holly Springs, NC","sentiment":"neutral"}],"patents":[],"drugCount":25,"phaseCounts":{"phase_3":15,"phase_1":1,"phase_2":5,"marketed":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}